Elan and American Home Products today announced a strategic alliance to develop and commercialise therapeutics for treating sleep disorders.
Under the terms of the alliance, AHP is contributing the US marketing rights to Sonata, a treatment for sleep disorders. Sonata is expected to generate revenues of about $85.4 million this year.
As part of the alliance, Elan will contribute its own drug-delivery technologies to develop new formulations of Sonata.
Elan will also be responsible for the marketing, sales and distribution of Sonata in the US.
